LONDON, March 13, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced it has presented data evaluating the role of T-Cell dysfunction in post-acute infection syndromes (PAIS) at the World Immune Regulation Meeting (WIRM) in Davos, Switzerland.

PAISs are often associated with a dysfunction of the immune system, notably progressive T-Cell exhaustion.  Chronic antigen stimulation following a chronic infection can cause upregulation of T-Cell exhaustion markers.  Data demonstrated that repeated stimulation of peripheral blood mononuclear cells (PBMCs) with SARS-CoV-2 and CMV peptide pools increases the proportion of CD4⁺ and CD8⁺ T-Cells expressing exhaustion markers PD-1, LAG-3, TIGIT, TIM-3, and CD39 with each stimulation cycle. T-Cell exhaustion is well documented to correlate with reduced cytokine production, particularly of pro-inflammatory cytokines, resulting in impaired immune functionality. Additionally, preliminary data from the ViraxImmune™ PAIS assay showed significant changes in the levels of a number of cytokines investigated in patients with PAIS compared to healthy controls.

"This data highlights the critical role of T-Cell exhaustion in immune dysfunction, particularly in PAIS conditions like long COVID, ME/CFS and chronic Lyme disease," said Nigel McCracken, Chief Operating Officer at Virax Biolabs. "In conjunction, we have initiated a number of clinical validation studies to evaluate the performance our T-Cell-based diagnostic in assessing the link between T-Cell dysfunction and symptoms of chronic fatigue and cognitive impairment."

A link to the poster presentation can be found here on the Virax Biolabs corporate website.

About Virax Biolabs Group Limited 

Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation. 

For more information, please visit www.viraxbiolabs.com. 

Caution Concerning Forward-looking Statements

This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "intends," "potential," or "hopes" or the negative of these or similar terms. Forward-looking statements are only predictions. The forward-looking events discussed in this press release, and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions. These forward-looking statements are based on information currently available to Virax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; successful development of our intended products; our ability to gain regulatory approval to offer our products or services in our targeted markets; our ability to keep pace with new technology and changing market needs; protection of our intellectual property rights; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. These and other important factors are described in detail in the "Risk Factors" section of Virax's Annual Report on Form 20-F for the year ended March 31, 2024. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Investor Relations Contact: 

Russo Partners, LLC 
Nic Johnson 
12 West 27th Street 
4th Floor 
New York, NY 10001 
M: 303-482-6405 
This email address is being protected from spambots. You need JavaScript enabled to view it.